AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bithionol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3032 | 97-18-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Halogenated anti-infective agent that is used against trematode and cestode infestations.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 69 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6,MAPK7,PDK4,PIK3CB,TEK | 8 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D10AB01 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Preparations containing sulfur |
| ATC | P02BX01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTITREMATODALS Other antitrematodal agents |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
| CHEBI has role | CHEBI:35684 | antiplatyhelmintic drug |
| CHEBI has role | CHEBI:86328 | antifungal agrochemical |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000980 | Antiplatyhelmintic Agents |
Related Drugs by ATC class:
P02BX Other antitrematodal agents 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.75 | acidic |
| pKa2 | 7.52 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | GPCR | Ki | 5.65 | DRUG MATRIX | |||||
| Adenosine receptor A2a | GPCR | Ki | 6.18 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.84 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.91 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.50 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.37 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.34 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.25 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 5.84 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.76 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 6.33 | DRUG MATRIX | |||||
| Transthyretin | Secreted | Kd | 7.21 | CHEMBL | |||||
| Estrogen receptor | Nuclear hormone receptor | IC50 | 5.40 | CHEMBL | |||||
| Estrogen receptor beta | Nuclear hormone receptor | IC50 | 5.09 | CHEMBL | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 6.21 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.65 | DRUG MATRIX | |||||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.67 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.74 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 6.50 | DRUG MATRIX | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 5.41 | CHEMBL | |||||
| Substance-K receptor | GPCR | Ki | 5.81 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 6.42 | DRUG MATRIX | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.72 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.28 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 5.18 | CHEMBL | |||||
| Solute carrier family 22 member 3 | Transporter | IC50 | 5.26 | CHEMBL | |||||
| N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D | Enzyme | INHIBITOR | IC50 | 4.97 | IUPHAR | ||||
| Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 5.30 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.26 | CHEMBL | |||||
| M1-family alanyl aminopeptidase | Enzyme | IC50 | 4.37 | CHEMBL | |||||
| Envelope glycoprotein gp160 | Viral envelope protein | IC50 | 5.21 | CHEMBL | |||||
| Potassium channel subfamily T member 1 | Ion channel | ACTIVATOR | EC50 | 6 | IUPHAR | ||||
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Viral envelope protein | IC50 | 5.21 | CHEMBL | |||||
| Pup--protein ligase | Enzyme | IC50 | 4.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00802 | KEGG_DRUG |
| C0005661 | UMLSCUI |
| CHEBI:3131 | CHEBI |
| CHEMBL290106 | ChEMBL_ID |
| DB04813 | DRUGBANK_ID |
| D001735 | MESH_DESCRIPTOR_UI |
| 2406 | PUBCHEM_CID |
| 2338 | IUPHAR_LIGAND_ID |
| 201 | INN_ID |
| AMT77LS62O | UNII |
| 002972 | NDDF |
| 10016008 | SNOMEDCT_US |
| AMT77LS62O | INXIGHT DRUGS |
Pharmaceutical products:
None